Trial Profile
A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 28 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 02 Jul 2014 New trial record